(R) BioInvent Interim Report January 1 - March 31, 2019
(WorldNews Sweden)

Net sales SEK 17.4 (11.3) million Earnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08 (-0.08) SEK Liquid funds as of March 31, 2019 SEK 28.5* (108.2) million. Cash flow from operating activities and investment activities SEK -40.5 (-29.3) million*Liquid funds as of March 31, 2019 include SEK 1.5 million of the total net capital SEK 220.0 million from the rights issue and the directed issue. Remaining net capital SEK 218.5 million has been received in April 2019. Important events in the first quarter and after the reporting period In January 2019 the U.S. Food and Drug Administration granted the Company orphan designation for its...